Kusurinomadoguchi (5592) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Feb, 2026Executive summary
Achieved record consolidated revenue and operating profit for the third quarter, driven by strong performance in the Media and Minna no Okusuri Bako businesses, with stock-type gross profit also reaching new highs year-over-year.
Revenue for the nine months ended December 31, 2025, increased 6.0% year-over-year to ¥8,927 million, driven by stable growth in the media business and new customer acquisition in the pharmacy support segment.
Operating profit rose 29.5% year-over-year to ¥2,015 million, and net profit attributable to shareholders surged 35.2% to ¥2,112 million, aided by cost optimization and deferred tax assets from a prior subsidiary merger.
Cost optimization, especially in subsidiaries, contributed to improved operating margins and reduced SG&A expenses compared to the previous year.
The company completed the acquisition of Medi-Web via a share exchange effective January 1, 2026, expanding its reach into the medical institution portal market.
Financial highlights
Consolidated revenue for Q3 YTD was ¥89.2 billion, up 6% year-over-year.
Operating profit rose 24% year-over-year to ¥754 million; EBITDA increased 20% to ¥1,127 million.
Net income attributable to parent company shareholders decreased 51% year-over-year due to prior-year tax adjustments.
Gross profit for the period was ¥5,084 million, up from ¥5,002 million in the prior year.
Total assets at period-end were ¥14,887 million, up from ¥12,157 million at the previous fiscal year-end.
Outlook and guidance
Full-year revenue forecast revised to ¥12.3 billion, up 9.8% from the previous year.
Operating profit guidance raised to ¥2.45 billion (+25.4% YoY); net income forecast at ¥2.69 billion (+32.2% YoY).
Annual dividend increased from ¥30 to ¥36 per share.
Newly consolidated subsidiaries' results not yet reflected in guidance.
Latest events from Kusurinomadoguchi
- Record profit and net income driven by recurring sales growth and capital reduction effects.5592
Q2 202614 Nov 2025 - Q1 FY2025 revenue up 22.1% YoY, but profit fell due to higher SG&A from acquisitions.5592
Q1 20258 Sep 2025 - Revenue up 28% YoY, profit growth, digital healthcare demand, and guidance maintained.5592
Q2 20258 Sep 2025 - Strong profit and revenue growth, improved financials, and robust digital healthcare outlook.5592
Q4 20258 Sep 2025 - Record Q1 revenue and profit growth with strong margins; full-year guidance unchanged.5592
Q1 20268 Sep 2025 - Record Q3 profit and revenue drive upward revision of full-year outlook and dividend.5592
Q3 20258 Sep 2025